Patent
Status of our key patents of core pipeline is as follows.
| Title of Invention | Oncolytic virus replicating selectively in tumor cells |
|---|---|
| Disease Area | Solid tumors (esophageal cancer, gastric cancer, liver cancer) |
| Patent Owner | Oncolys BioPharma Inc. |
| Rights of Oncolys BioPharma | Owner of patents |
| Country / Patent Number | Japan:3867968 USA:8163892 United Kingdom:1553178 Germany:1553178 France:1553178 Netherlands:1553178 Spain:1553178 Ireland:1553178 Switzerland:1553178 Italy:1553178 Sweden:1553178 Belgium:1553178 Denmark:1553178 Austria:1553178 Hungary:1553178 Portugal:1553178 Australia:2003281310 Canada:2491907 China:100430476 Hong Kong:1082958 Republic of Korea:10-0947194 New Zealand:537631 Singapore:109.276 South Africa:2005/00047 |
| status | Patents concerning drug substance issued in 24 countries including Japan, Europe and the U.S.A. Japanese patent has expired after the full patent term |
| Title of Invention | Anti-viral nucleoside analog and methods for treating viral infections, especially HIV infections |
|---|---|
| Disease Area | PSP (progressive supranuclear palsy), C9-ALS (C9orf72 amyotrophic lateral sclerosis), FTD (frontotemporal dementia) |
| Patent Owner | Yale University, etc. |
| Rights of Oncolys BioPharma | Worldwide exclusive license |
| Country / Patent Number | Japan:4980059 USA:7589078, 9126971 United Kingdom:2298783 Germany:2298783 France:2298783 Australia:2004260630 Canada:2514466 China:1777432 Hong Kong:1087341 Russian Federation:12844 Israel:169944 Republic of Korea:10-1228503 Mexico:281038 New Zealand:541594 Poland:219609 Singapore:115981 |
| Status | Patents concerning drug substance issued in 16 countries including Japan, Europe and the U.S.A. |
| Title of Invention | Novel depsipeptide compound |
|---|---|
| Disease Area | Various types of cancers, ophthalmologic field |
| Patent Owner | Astellas Pharma Inc. |
| Rights of Oncolys BioPharma | Worldwide exclusive license |
| Country / Patent Number | Japan:3554707 USA:6670326, 7098024 Ireland:1142905 United Kingdom:1142905 Italy:1142905 Austria:1142905 Netherlands:1142905 Greece:1142905 Switzerland:1142905 Sweden:1142905 Spain:1142905 Denmark:1142905 Germany:60029084 Finland:1142905 France:1142905 Belgium:1142905 Portugal:1142905 Canada:2356845 China:ZL00802510.X Republic of Korea:10-0611265 |
| Status | Patents concerning drug substance issued in 20 countries including Japan, Europe and the U.S.A. All patents have expired after the full patent term |
| Title of Invention | Telomelysin / GFP-expressing recombinant virus |
|---|---|
| Disease Area | Detection of cancer |
| Patent Owner | Oncolys BioPharma Inc. |
| Rights of Oncolys BioPharma | Owner of Patents |
| Country / Patent Number | Japan:5006045 United Kingdom:2311499 Germany:2311499 France:2311499 Italy:2311499 Netherlands:2311499 India:246555 New Zealand:554799 Singapore:130465 |
| Status | Patents concerning substance issued in 9 countries including Japan and Europe and also protected by patents for OBP-301 (Telomelysin). |
| Title of Invention | Conditionally replication-competent adenovirus |
|---|---|
| Disease Area | Detection of cancer |
| Patent Owner | National Institute of Biomedical Innovation |
| Rights of Oncolys BioPharma | Worldwide exclusive license |
| Country / Patent Number | Japan:5812361, 5971599 USA:9624476 United Kingdom:2749647 Germany:2749647 France:2749647 Switzwrland:2749647 China:103857795 Hong Kong:1198835 Republic of Korea:10-1946666 Australia:2012298013 Singapore:11201400139 New Zealand:622585 |
| Status | Patents concerning substance issued in 12 countries including Japan and also protected by patents for OBP-301 (Telomelysin) and OBP-401 (TelomeScan) |
| Title of Invention | ANTI-SARS-COV-2 DRUG |
|---|---|
| Disease Area | SARS-CoV-2 |
| Patent Owner | Oncolys BioPharma Inc. |
| Rights of Oncolys BioPharma | Owner of Patents |
| Country / application number | Japan:2022-524462 USA:17/926101 Europe: 21808187.5 |
| Status | All patent applications are pending |
